CSRP2

Summary

CSRP2 (cysteine and glycine rich protein 2, HGNC:2470) is a protein-coding gene on chromosome 12q21.2, encoding Cysteine and glycine-rich protein 2 (Q16527). Drastically down-regulated in response to PDGF-BB or cell injury, that promote smooth muscle cell proliferation and dedifferentiation.

CSRP2 is a member of the CSRP family of genes, encoding a group of LIM domain proteins, which may be involved in regulatory processes important for development and cellular differentiation. CRP2 contains two copies of the cysteine-rich amino acid sequence motif (LIM) with putative zinc-binding activity, and may be involved in regulating ordered cell growth. Other genes in the family include CSRP1 and CSRP3. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 1466 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 25 total
• Druggable target: yes
• MANE Select transcript: NM_001321

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2470
Approved symbol	CSRP2
Name	cysteine and glycine rich protein 2
Location	12q21.2
Locus type	gene with protein product
Status	Approved
Aliases	SmLIM, CRP2, LMO5
Ensembl gene	ENSG00000175183
Ensembl biotype	protein_coding
OMIM	601871
Entrez	1466

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 24 protein_coding, 3 retained_intron

ENST00000311083, ENST00000546966, ENST00000547435, ENST00000547557, ENST00000548783, ENST00000551725, ENST00000552330, ENST00000909815, ENST00000909816, ENST00000909817, ENST00000909818, ENST00000909819, ENST00000909820, ENST00000909821, ENST00000909822, ENST00000919906, ENST00000919907, ENST00000919908, ENST00000919909, ENST00000919910, ENST00000919911, ENST00000919912, ENST00000919913, ENST00000919914, ENST00000919915, ENST00000919916, ENST00000965133

RefSeq mRNA: 9 — MANE Select: NM_001321 NM_001300965, NM_001321, NM_001413535, NM_001413537, NM_001413538, NM_001413539, NM_001413540, NM_001413541, NM_001413542

CCDS: CCDS9015

Canonical transcript exons

ENST00000311083 — 6 exons

Exon	Start	End
ENSE00001210521	76860284	76860413
ENSE00001210527	76863176	76863344
ENSE00001210540	76866149	76866261
ENSE00002337743	76878938	76879019
ENSE00002397508	76858709	76859028
ENSE00003587346	76859547	76859640

Expression profiles

Bgee: expression breadth ubiquitous, 297 present calls, max score 99.86.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.6958 / max 850.8149, expressed in 1455 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
132231	19.6057	1455
132227	0.0318	5
132229	0.0282	10
132230	0.0257	7
132228	0.0044	2

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	99.86	gold quality
secondary oocyte	CL:0000655	99.82	gold quality
cervix squamous epithelium	UBERON:0006922	99.57	gold quality
cortical plate	UBERON:0005343	99.51	gold quality
blood vessel layer	UBERON:0004797	99.46	gold quality
ganglionic eminence	UBERON:0004023	99.08	gold quality
popliteal artery	UBERON:0002250	99.07	gold quality
tibial artery	UBERON:0007610	99.07	gold quality
embryo	UBERON:0000922	98.99	gold quality
artery	UBERON:0001637	98.96	gold quality
squamous epithelium	UBERON:0006914	98.92	gold quality
esophagus squamous epithelium	UBERON:0006920	98.91	gold quality
right coronary artery	UBERON:0001625	98.88	gold quality
mucosa of paranasal sinus	UBERON:0005030	98.77	gold quality
parietal pleura	UBERON:0002400	98.70	gold quality
gingival epithelium	UBERON:0001949	98.60	gold quality
aorta	UBERON:0000947	98.54	gold quality
mucosa of stomach	UBERON:0001199	98.53	gold quality
gingiva	UBERON:0001828	98.50	gold quality
epithelium of esophagus	UBERON:0001976	98.50	gold quality
cranial nerve II	UBERON:0000941	98.49	gold quality
coronary artery	UBERON:0001621	98.40	gold quality
left coronary artery	UBERON:0001626	98.35	gold quality
descending thoracic aorta	UBERON:0002345	98.13	gold quality
thoracic aorta	UBERON:0001515	97.86	gold quality
pleura	UBERON:0000977	97.79	gold quality
ascending aorta	UBERON:0001496	97.79	gold quality
cervix epithelium	UBERON:0004801	97.78	gold quality
urethra	UBERON:0000057	97.50	gold quality
endothelial cell	CL:0000115	97.35	gold quality

Single-cell (SCXA)

Detected in 17 experiment(s), a significant marker in 14.

Experiment	Marker?	Max mean expression
E-MTAB-10485	yes	1550.15
E-HCAD-5	yes	1426.55
E-GEOD-84465	yes	721.78
E-MTAB-9435	yes	680.11
E-MTAB-8205	yes	578.97
E-MTAB-10287	yes	66.82
E-MTAB-6701	yes	63.32
E-GEOD-137537	yes	33.32
E-HCAD-11	yes	28.18
E-MTAB-7316	yes	26.04
E-MTAB-8410	yes	25.82
E-CURD-46	yes	11.76
E-MTAB-9388	yes	10.91
E-MTAB-10290	no	370.11
E-MTAB-10137	no	8.15

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPB, CREB1, SMAD2, SMAD3, SP1, SRF

miRNA regulators (miRDB)

28 targeting CSRP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-199A-3P	99.75	70.48	929
HSA-MIR-199B-3P	99.75	70.48	929
HSA-MIR-3129-5P	99.75	70.46	914
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-122B-5P	99.46	70.81	1457
HSA-MIR-133A-5P	99.28	69.13	941
HSA-MIR-6737-3P	98.95	68.56	1577
HSA-MIR-7157-3P	98.95	68.70	1582
HSA-MIR-4709-3P	98.88	68.04	1594
HSA-MIR-6889-3P	98.84	67.35	1198
HSA-MIR-5008-3P	98.73	67.50	1433
HSA-MIR-6529-3P	98.68	66.76	1020
HSA-MIR-138-5P	98.43	70.49	1292
HSA-MIR-5000-5P	97.40	66.11	1055
HSA-MIR-6131	97.22	66.72	960
HSA-MIR-550B-2-5P	96.56	64.61	646
HSA-MIR-6858-3P	96.37	64.41	771

Literature-anchored findings (GeneRIF, showing 6)

• the effect of proteasome inhibition on IL-10 activation of the IL-10E1 pathway [Il-10E1] (PMID:12861049)
• CSRP2 promoted cell proliferation, cell-cycle progression, in vitro colony formation and cell migration ability. Abnormal CSRP2 expression was associated with resistance to chemotherapy; sensitivity was restored by down-regulating CSRP2 expression. (PMID:28415593)
• Study showed that CSRP2, an invadopodial actin bundling protein, is upregulated by hypoxia in various breast cancer cell lines, as well as in pre-clinical and clinical breast tumor specimens and functionally characterized two hypoxia responsive elements within the proximal promoter of CSRP2 gene which are targeted by hypoxia-inducible factor-1 (HIF-1) and required for promoter transactivation in response to hypoxia. (PMID:29976963)
• CSRP2 suppresses colorectal cancer progression via p130Cas/Rac1 axis-meditated ERK, PAK, and HIPPO signaling pathways. (PMID:33042270)
• Role of CRP2-MRTF interaction in functions of myofibroblasts. (PMID:37164693)
• Significance of the p38MAPK-CRP2 axis in myofibroblastic phenotypic transition. (PMID:37899269)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	csrp2	ENSDARG00000011961
mus_musculus	Csrp2	ENSMUSG00000020186
rattus_norvegicus	Csrp2	ENSRNOG00000003772
drosophila_melanogaster	Mlp84B	FBGN0014863
drosophila_melanogaster	Mlp60A	FBGN0259209
caenorhabditis_elegans		WBGENE00003375

Paralogs (2): CSRP3 (ENSG00000129170), CSRP1 (ENSG00000159176)

Protein

Protein identifiers

Cysteine and glycine-rich protein 2 — Q16527 (reviewed: Q16527)

Alternative names: Cysteine-rich protein 2, LIM domain only protein 5, Smooth muscle cell LIM protein

All UniProt accessions (4): A0A024RBB5, Q16527, F8VQR7, F8VW96

UniProt curated annotations — full annotation on UniProt →

Function. Drastically down-regulated in response to PDGF-BB or cell injury, that promote smooth muscle cell proliferation and dedifferentiation. Seems to play a role in the development of the embryonic vascular system.

Subunit / interactions. Interacts with KAT14. The LIM domain 1 is necessary and sufficient for this interaction. Interacts with GLRX3.

Subcellular location. Nucleus.

Tissue specificity. Highly expressed in the aorta, but not in heart and skeletal muscle.

RefSeq proteins (9): NP_001287894, NP_001312, NP_001400464, NP_001400466, NP_001400467, NP_001400468, NP_001400469, NP_001400470, NP_001400471 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001781	Znf_LIM	Domain

Pfam: PF00412

UniProt features (10 total): modified residue 5, domain 2, chain 1, short sequence motif 1, cross-link 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q16527-F1	71.07	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 112, 131, 137, 137, 161, 91

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 259 (showing top): MODULE_52, GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_SARCOMERE_ORGANIZATION, MODULE_66, MODULE_118, WEI_MYCN_TARGETS_WITH_E_BOX, BROWNE_HCMV_INFECTION_48HR_DN, CAIRO_HEPATOBLASTOMA_CLASSES_DN, PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP, MODULE_75, PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_DN, GOBP_CELLULAR_COMPONENT_ASSEMBLY_INVOLVED_IN_MORPHOGENESIS, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, LE_EGR2_TARGETS_UP

GO Biological Process (3): cell differentiation (GO:0030154), sarcomere organization (GO:0045214), muscle tissue development (GO:0060537)

GO Molecular Function (4): structural constituent of muscle (GO:0008307), actinin binding (GO:0042805), metal ion binding (GO:0046872), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), cytoplasm (GO:0005737), focal adhesion (GO:0005925), Z disc (GO:0030018)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
cellular developmental process	1
myofibril assembly	1
actomyosin structure organization	1
tissue development	1
structural molecule activity	1
cytoskeletal protein binding	1
cation binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cell-substrate junction	1
I band	1

Protein interactions and networks

STRING

916 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CSRP2	SRF	P11831	570
CSRP2	SPARC	P09486	545
CSRP2	PIAS1	O75925	544
CSRP2	LMO1	P25800	493
CSRP2	GATA5	Q9BWX5	433
CSRP2	MED14	O60244	426
CSRP2	RNF168	Q8IYW5	426
CSRP2	PRL	P01236	425
CSRP2	PIAS4	Q8N2W9	423
CSRP2	TAGLN	Q01995	423
CSRP2	CDH17	Q12864	405
CSRP2	RPL26	P61254	402
CSRP2	FBXW5	Q969U6	399
CSRP2	BAG1	Q99933	396
CSRP2	RNF8	O76064	395

IntAct

49 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CSRP2	TRIM27	psi-mi:“MI:0915”(physical association)	0.560
CSRP2	ARC	psi-mi:“MI:0915”(physical association)	0.560
CSRP2	COG6	psi-mi:“MI:0915”(physical association)	0.560
TRIM23	CSRP2	psi-mi:“MI:0915”(physical association)	0.560
GPS1	PXDNL	psi-mi:“MI:0914”(association)	0.530
CSRP2	STK4	psi-mi:“MI:0915”(physical association)	0.370
OTUB1		psi-mi:“MI:0914”(association)	0.350
OTUB1	EPM2A	psi-mi:“MI:0914”(association)	0.350
JUN		psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
TK	AP3B1	psi-mi:“MI:0914”(association)	0.350
		psi-mi:“MI:0914”(association)	0.350
	VWA8	psi-mi:“MI:0914”(association)	0.350
	ESYT2	psi-mi:“MI:0914”(association)	0.350
	PGRMC1	psi-mi:“MI:0914”(association)	0.350
BVLF1	VWA8	psi-mi:“MI:0914”(association)	0.350
	KPNA4	psi-mi:“MI:0914”(association)	0.350
BCAR1	MYO1C	psi-mi:“MI:0914”(association)	0.350
BCAR1	ARHGEF11	psi-mi:“MI:0914”(association)	0.350
BCAR1	CEP290	psi-mi:“MI:0914”(association)	0.350
VMP1	TPM3	psi-mi:“MI:0914”(association)	0.350
ARHGAP11B	RPN1	psi-mi:“MI:0914”(association)	0.350
GABARAPL1		psi-mi:“MI:0914”(association)	0.350
VCP	SHTN1	psi-mi:“MI:0914”(association)	0.350
VCP	FAM171A2	psi-mi:“MI:0914”(association)	0.350

BioGRID (86): TRIM27 (Two-hybrid), CSRP2 (Affinity Capture-MS), CSRP2 (Affinity Capture-MS), CSRP2 (Affinity Capture-MS), CSRP2 (Affinity Capture-MS), CSRP2 (Proximity Label-MS), CSRP2 (Affinity Capture-MS), CSRP2 (Affinity Capture-MS), CSRP2 (Affinity Capture-MS), CSRP2 (Proximity Label-MS), CSRP2 (Affinity Capture-MS), CSRP2 (Affinity Capture-MS), CSRP2 (Affinity Capture-MS), CSRP2 (Affinity Capture-MS), CSRP2 (Affinity Capture-MS)

ESM2 similar proteins: O00151, O04193, O35115, O70400, O70433, O80839, P21291, P29675, P36201, P47875, P50238, P50461, P50462, P50463, P50464, P52943, P52944, P53777, P63254, P63255, P67966, P67967, P97315, Q0VFX8, Q14192, Q16527, Q1ECF5, Q1LZA7, Q24400, Q2KI95, Q3MHY1, Q4KM31, Q4U0T9, Q500W4, Q56K04, Q5E9E1, Q5R7Y1, Q5RCT4, Q5RGJ5, Q5ZLR4

Diamond homologs: B0KYV5, D4A1F2, F1LR10, F1MF74, F1QH17, F1QWK4, F1RA39, F6QZ15, G3MWR8, G5EF51, O04193, O60952, O77506, O80839, O94851, P21291, P29675, P36201, P47875, P50460, P50461, P50462, P50463, P52943, P53777, P67966, P67967, P97314, P97315, Q05158, Q0E908, Q0VFX8, Q14847, Q16527, Q1ECF5, Q1LZA7, Q32LE9, Q3B7M5, Q3MHY1, Q4KM31

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

25 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	18
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1065 predictions. Top by Δscore:

Variant	Effect	Δscore
12:76860278:CTTTA:C	donor_loss	1.0000
12:76860279:TTTA:T	donor_loss	1.0000
12:76860280:TTA:T	donor_loss	1.0000
12:76860281:TACCT:T	donor_loss	1.0000
12:76860283:C:A	donor_loss	1.0000
12:76860412:CACT:C	acceptor_gain	1.0000
12:76860415:T:C	acceptor_gain	1.0000
12:76860415:T:TC	acceptor_gain	1.0000
12:76860417:G:GC	acceptor_gain	1.0000
12:76863171:CTCA:C	donor_loss	1.0000
12:76863172:TCA:T	donor_loss	1.0000
12:76863173:CAC:C	donor_loss	1.0000
12:76863174:A:AT	donor_loss	1.0000
12:76863175:CCT:C	donor_gain	1.0000
12:76863175:CCTCT:C	donor_gain	1.0000
12:76863342:CCA:C	acceptor_gain	1.0000
12:76863343:CA:C	acceptor_gain	1.0000
12:76863343:CAC:C	acceptor_gain	1.0000
12:76863345:C:CC	acceptor_gain	1.0000
12:76866147:A:AC	donor_gain	1.0000
12:76866148:C:CC	donor_gain	1.0000
12:76866148:CTG:C	donor_gain	1.0000
12:76878936:A:AC	donor_gain	1.0000
12:76878937:C:CC	donor_gain	1.0000
12:76859636:CAGGG:C	acceptor_gain	0.9900
12:76859641:C:CC	acceptor_gain	0.9900
12:76860412:CA:C	acceptor_gain	0.9900
12:76860414:C:CC	acceptor_gain	0.9900
12:76860417:G:C	acceptor_gain	0.9900
12:76863174:A:AC	donor_gain	0.9900

AlphaMissense

1264 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:76858992:C:T	G181D	1.000
12:76859007:C:T	G176E	1.000
12:76859026:A:G	C170R	1.000
12:76859552:C:G	C167S	1.000
12:76859552:C:T	C167Y	1.000
12:76859553:A:G	C167R	1.000
12:76859553:A:T	C167S	1.000
12:76859594:A:T	L153H	1.000
12:76859606:C:G	C149S	1.000
12:76859607:A:G	C149R	1.000
12:76859607:A:T	C149S	1.000
12:76859614:A:C	C146W	1.000
12:76859615:C:G	C146S	1.000
12:76859615:C:T	C146Y	1.000
12:76859616:A:G	C146R	1.000
12:76859616:A:T	C146S	1.000
12:76859624:C:G	C143S	1.000
12:76859625:A:G	C143R	1.000
12:76859625:A:T	C143S	1.000
12:76859637:A:G	W139R	1.000
12:76859637:A:T	W139R	1.000
12:76860330:C:G	C122S	1.000
12:76860331:A:T	C122S	1.000
12:76860339:C:G	C119S	1.000
12:76860340:A:G	C119R	1.000
12:76860340:A:T	C119S	1.000
12:76863242:C:T	G72D	1.000
12:76863257:C:T	G67E	1.000
12:76863276:A:G	C61R	1.000
12:76863283:G:C	C58W	1.000

dbSNP variants (sampled 300 via entrez): RS1000005269 (12:76863125 A>G), RS1000172569 (12:76874639 T>A,C), RS1000267545 (12:76880161 G>A), RS1000616247 (12:76870583 T>C), RS1000626906 (12:76876057 T>G), RS1000690319 (12:76874386 C>G,T), RS1000838911 (12:76864484 T>C), RS1000883014 (12:76869080 G>T), RS1000913153 (12:76876325 C>A), RS1000946253 (12:76862561 T>G), RS1000996374 (12:76875037 C>G), RS1001338566 (12:76864293 A>G,T), RS1001450277 (12:76877052 T>G), RS1001618511 (12:76870683 T>C), RS1001691318 (12:76864186 A>G)

Disease associations

OMIM: gene MIM:601871 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST003833_8	Adult asthma	2.000000e-06
GCST012292_6	Schizophrenia, bipolar disorder or recurrent major depressive disorder x sex interaction	3.000000e-06
GCST012295_3	Schizophrenia, bipolar disorder or recurrent major depressive disorder x sex interaction	7.000000e-07
GCST012298_7	Schizophrenia, bipolar disorder or major depressive disorder x sex interaction	9.000000e-07
GCST012299_22	Schizophrenia, bipolar disorder or major depressive disorder x sex interaction (3df)	2.000000e-06
GCST012300_1	Schizophrenia, bipolar disorder or major depressive disorder	5.000000e-06
GCST012301_14	Schizophrenia, bipolar disorder or major depressive disorder x sex interaction	2.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004952	disease recurrence
EFO:0008343	sex interaction measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295833 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

85 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	decreases expression	4
bisphenol A	affects expression, decreases expression, decreases methylation	3
trichostatin A	decreases expression, affects cotreatment	2
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	2
Temozolomide	decreases response to substance, increases expression	2
Arsenic Trioxide	decreases expression, increases expression	2
Arsenic	increases abundance, increases expression, affects cotreatment, decreases expression	2
Doxorubicin	affects expression, increases expression	2
Estradiol	decreases expression, affects expression	2
Tobacco Smoke Pollution	increases expression	2
Valproic Acid	affects expression, decreases expression	2
Aflatoxin B1	decreases expression	2
aristolochic acid I	decreases expression	1
TAK-243	increases sumoylation	1
TL8-506	affects cotreatment, increases expression	1
tungsten carbide	affects cotreatment, increases expression	1
lead acetate	increases expression	1
sodium arsenate	increases expression, increases abundance	1
beta-lapachone	decreases expression	1
arsenite	affects binding, increases reaction	1
mono-(2-ethylhexyl)phthalate	decreases expression, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
zinc chloride	decreases reaction, increases expression	1
2-amino-9H-pyrido(2,3-b)indole	decreases expression	1
cobaltous chloride	decreases reaction, increases expression	1
butyraldehyde	increases expression	1
tetrabromobisphenol A	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
hydroquinone	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118574	Binding	Binding affinity to CSRP2 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.